<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 28 Nov 2024 04:14:23 +0000</lastbuilddate>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Ablation of persistent atrial fibrillation: lessons learnt from the CAPLA trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39602598/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 27:ehae832. doi: 10.1093/eurheartj/ehae832. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39602598/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39602598</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae832>10.1093/eurheartj/ehae832</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39602598</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jayanthi N Koneru</dc:creator>
<dc:creator>Kenneth A Ellenbogen</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ablation of persistent atrial fibrillation: lessons learnt from the CAPLA trial</dc:title>
<dc:identifier>pmid:39602598</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae832</dc:identifier>
</item>
<item>
<title>Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39602157/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this study, in patients who experienced PCI and were event-free during 6 to 18 months of DAPT, the beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent, regardless of bleeding risk and/or PCI complexity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 27. doi: 10.1001/jamacardio.2024.4030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Antiplatelet monotherapy in the chronic maintenance period for patients with high bleeding risk (HBR) and those who have undergone complex percutaneous coronary intervention (PCI) has not yet been explored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare clopidogrel vs aspirin monotherapy in patients with HBR and/or PCI complexity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the multicenter HOST-EXAM Extended study, an open-label trial conducted across 37 sites in South Korea, enrolled patients from 2014 to 2018 with up to 5.9 years of follow-up. The analysis was conducted from February to November 2023. Patients who maintained dual antiplatelet therapy (DAPT) event-free for 6 to 18 months following PCI were included.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized to receive either clopidogrel or aspirin in a 1:1 ratio. Those with sufficient data to assess HBR or complex PCI were analyzed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Coprimary end points were thrombotic composite end point (cardiovascular death, nonfatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and definite/probable stent thrombosis) and any bleeding (Bleeding Academic Research Consortium type 2 to 5).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 3974 patients included (mean [SD] age, 63.4 [10.7] years; 2976 male [74.9%]), 866 had HBR (21.8%), and 849 underwent complex PCI (21.4%). Clopidogrel as compared with aspirin was associated with lower rates of thrombotic and bleeding events regardless of HBR and/or PCI complexity. For the thrombotic composite end point, the hazard ratio (HR) was 0.75 (95% CI, 0.53-1.04) among HBR vs 0.62 (95% CI, 0.48-0.80) among patients without HBR (P for interaction = 0.38) and 0.49 (95% CI, 0.32-0.77) among patients with complex PCI vs 0.74 (95% CI, 0.59-0.92) among patients with noncomplex PCI (P for interaction = 0.12). The reduction in bleeding by clopidogrel compared with aspirin was consistent among both patients with HBR (HR, 0.82; 95% CI, 0.56-1.21) and patients without HBR (HR, 0.58; 95% CI, 0.40-0.85; P for interaction = 0.20) and among patients undergoing complex PCI (HR, 0.79; 95% CI, 0.47-1.33) vs noncomplex PCI (HR, 0.68; 95% CI, 0.50-0.93; P for interaction = 0.62).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, in patients who experienced PCI and were event-free during 6 to 18 months of DAPT, the beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent, regardless of bleeding risk and/or PCI complexity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02044250.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39602157/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39602157</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4030>10.1001/jamacardio.2024.4030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39602157</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jeehoon Kang</dc:creator>
<dc:creator>Jaewook Chung</dc:creator>
<dc:creator>Kyung Woo Park</dc:creator>
<dc:creator>Jang-Whan Bae</dc:creator>
<dc:creator>Huijin Lee</dc:creator>
<dc:creator>Doyeon Hwang</dc:creator>
<dc:creator>Han-Mo Yang</dc:creator>
<dc:creator>Kyoo-Rok Han</dc:creator>
<dc:creator>Keon-Woong Moon</dc:creator>
<dc:creator>Ung Kim</dc:creator>
<dc:creator>Moo-Yong Rhee</dc:creator>
<dc:creator>Doo-Il Kim</dc:creator>
<dc:creator>Song-Yi Kim</dc:creator>
<dc:creator>Sung-Yun Lee</dc:creator>
<dc:creator>Seung Uk Lee</dc:creator>
<dc:creator>Sang-Wook Kim</dc:creator>
<dc:creator>Seok Yeon Kim</dc:creator>
<dc:creator>Jung-Kyu Han</dc:creator>
<dc:creator>Eun-Seok Shin</dc:creator>
<dc:creator>Bon-Kwon Koo</dc:creator>
<dc:creator>Hyo-Soo Kim</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity</dc:title>
<dc:identifier>pmid:39602157</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4030</dc:identifier>
</item>
<item>
<title>The FINE ART of Interpreting Health Status Benefits in Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601741/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26:S0735-1097(24)10293-8. doi: 10.1016/j.jacc.2024.10.095. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601741/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39601741</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.095>10.1016/j.jacc.2024.10.095</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601741</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The FINE ART of Interpreting Health Status Benefits in Clinical Trials</dc:title>
<dc:identifier>pmid:39601741</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.095</dc:identifier>
</item>
<item>
<title>Enhanced Parkin-mediated mitophagy mitigates adverse left ventricular remodelling after myocardial infarction: role of PR-364</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study demonstrates the therapeutic potential of targeting Parkin-mediated mitophagy using PR-364 to protect surviving cardiac tissue post-MI from progression to HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 27:ehae782. doi: 10.1093/eurheartj/ehae782. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Almost 30% of survivors of myocardial infarction (MI) develop heart failure (HF), in part due to damage caused by the accumulation of dysfunctional mitochondria. Organelle quality control through Parkin-mediated mitochondrial autophagy (mitophagy) is known to play a role in mediating protection against HF damage post-ischaemic injury and remodelling of the subsequent deteriorated myocardium.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study has shown that a single i.p. dose (2 h post-MI) of the selective small molecule Parkin activator PR-364 reduced mortality, preserved cardiac ejection fraction, and mitigated the progression of HF. To reveal the mechanism of PR-364, a multi-omic strategy was deployed in combination with classical functional assays using in vivo MI and in vitro cardiomyocyte models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In vitro cell data indicated that Parkin activation by PR-364 increased mitophagy and mitochondrial biogenesis, enhanced adenosine triphosphate production via improved citric acid cycle, altered accumulation of calcium localization to the mitochondria, and initiated translational reprogramming with increased expression of mitochondrial translational proteins. In mice, PR-364 administered post-MI resulted in widespread proteome changes, indicating an up-regulation of mitochondrial metabolism and mitochondrial translation in the surviving myocardium.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study demonstrates the therapeutic potential of targeting Parkin-mediated mitophagy using PR-364 to protect surviving cardiac tissue post-MI from progression to HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39601359</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae782>10.1093/eurheartj/ehae782</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601359</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lizhuo Ai</dc:creator>
<dc:creator>Juliana de Freitas Germano</dc:creator>
<dc:creator>Chengqun Huang</dc:creator>
<dc:creator>Marianne Aniag</dc:creator>
<dc:creator>Savannah Sawaged</dc:creator>
<dc:creator>Jon Sin</dc:creator>
<dc:creator>Reetu Thakur</dc:creator>
<dc:creator>Deepika Rai</dc:creator>
<dc:creator>Christopher Rainville</dc:creator>
<dc:creator>David E Sterner</dc:creator>
<dc:creator>Yang Song</dc:creator>
<dc:creator>Honit Piplani</dc:creator>
<dc:creator>Suresh Kumar</dc:creator>
<dc:creator>Tauseef R Butt</dc:creator>
<dc:creator>Robert M Mentzer</dc:creator>
<dc:creator>Aleksandr Stotland</dc:creator>
<dc:creator>Roberta A Gottlieb</dc:creator>
<dc:creator>Jennifer E Van Eyk</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Enhanced Parkin-mediated mitophagy mitigates adverse left ventricular remodelling after myocardial infarction: role of PR-364</dc:title>
<dc:identifier>pmid:39601359</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae782</dc:identifier>
</item>
<item>
<title>Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601339/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Coronary artery bypass grafting is associated with lower risks of mortality, MI, repeat revascularization, and heart failure in patients with NSTEMI, particularly in high-risk subgroups. However, its survival benefit lessens with shorter life expectancy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 27:ehae700. doi: 10.1093/eurheartj/ehae700. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The long-term outcomes of percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease remain debated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry was used to analyse 57 097 revascularized patients with NSTEMI with multivessel disease in Sweden from January 2005 to June 2022. The primary endpoint was all-cause mortality, encompassing both in-hospital and long-term mortality; the secondary endpoints included myocardial infarction (MI), stroke, new revascularization, and heart failure. Multilevel logistic regression with follow-up time as a log-transformed offset variable and double-robust adjustment with the instrumental variable method were applied to control for known and unknown confounders.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Percutaneous coronary intervention was the primary therapy in 42 190 (73.9%) patients, while 14 907 (26.1%) received CABG. Percutaneous coronary intervention patients were generally older with more prior cardiovascular events, whereas CABG patients had higher incidences of diabetes, hypertension, left main and three-vessel disease, and reduced ejection fraction. Over a median follow-up of 7.1 years, PCI was associated with higher risks of death [adjusted odds ratio (aOR) 1.67; 95% confidence interval (CI) 1.54-1.81] and MI (aOR 1.51; 95% CI 1.41-1.62) but there was no significant difference in stroke. Repeat revascularization was three times more likely to PCI (aOR 3.01; 95% CI 2.57-3.51), while heart failure risk was 15% higher (aOR 1.15; 95% CI 1.07-1.25). Coronary artery bypass grafting provided longer survival within 15 years, especially in patients under 70 years of age, with left main disease or left ventricular dysfunction, though this benefit diminished over shorter time horizons.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Coronary artery bypass grafting is associated with lower risks of mortality, MI, repeat revascularization, and heart failure in patients with NSTEMI, particularly in high-risk subgroups. However, its survival benefit lessens with shorter life expectancy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601339/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39601339</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae700>10.1093/eurheartj/ehae700</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601339</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Elmir Omerovic</dc:creator>
<dc:creator>Truls Råmunddal</dc:creator>
<dc:creator>Petur Petursson</dc:creator>
<dc:creator>Oskar Angerås</dc:creator>
<dc:creator>Araz Rawshani</dc:creator>
<dc:creator>Sandeep Jha</dc:creator>
<dc:creator>Kristofer Skoglund</dc:creator>
<dc:creator>Moman A Mohammad</dc:creator>
<dc:creator>Jonas Persson</dc:creator>
<dc:creator>Joakim Alfredsson</dc:creator>
<dc:creator>Robin Hofmann</dc:creator>
<dc:creator>Tomas Jernberg</dc:creator>
<dc:creator>Ole Fröbert</dc:creator>
<dc:creator>Anders Jeppsson</dc:creator>
<dc:creator>Emma C Hansson</dc:creator>
<dc:creator>Göran Dellgren</dc:creator>
<dc:creator>David Erlinge</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry</dc:title>
<dc:identifier>pmid:39601339</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae700</dc:identifier>
</item>
<item>
<title>Social Bonds Retain Oxytocin-Mediated Brain-Liver Axis to Retard Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601150/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results identify a novel brain-liver axis that links sociality to hepatic lipid metabolism, thus proposing a potential therapeutic strategy for loneliness-associated atherosclerosis progression.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Nov 27. doi: 10.1161/CIRCRESAHA.124.324638. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUNDS: Social interaction with others is essential to life. Although social isolation and loneliness have been implicated as increased risks of cardiometabolic and cardiovascular diseases and all-cause mortality, the cellular and molecular mechanisms by which social connection maintains cardiometabolic and cardiovascular health remain largely unresolved.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To investigate how social connection protects against cardiometabolic and cardiovascular diseases, atherosclerosis-prone, high-fat diet-fed <i>Apoe</i><sup>-/-</sup> mouse siblings were randomly assigned to either individual or grouped housing for 12 weeks. Histological, flow cytometric, biochemical, gene, and protein analyses were performed to assess atherosclerotic lesions, systemic metabolism, inflammation, and stress response. The effects of oxytocin on hepatocytes and subsequent cardiometabolic and cardiovascular function were investigated by in vivo and in vitro approaches.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: <i>Apoe</i><sup>-/-</sup> mice housed individually developed larger vulnerable atherosclerotic lesions by disrupted lipid metabolism compared with those of mice in regular group housing, irrespective of body weight, eating behavior, feeding conditions, sympathetic nervous activity, glucocorticoid response, or systemic inflammation. Mechanistically, the chronic isolation reduced the hypothalamic production of oxytocin, which controls bile acid production and LPL (lipoprotein lipase) activity through the peripheral OXTR (oxytocin receptor) in hepatocytes, whose downstream targets include <i>Cyp7a1</i>, <i>Angptl4</i>, and <i>Angptl8</i>. While hepatocyte-specific OXTR-null mice and mice receiving adeno-associated virus targeting OXTR on hepatocytes led to severe dyslipidemia and aggravated atherosclerosis, oral oxytocin supplementation to socially isolated mice, but not to hepatocyte-specific OXTR conditional knockout mice, improved lipid profiles and retarded atherosclerosis development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results identify a novel brain-liver axis that links sociality to hepatic lipid metabolism, thus proposing a potential therapeutic strategy for loneliness-associated atherosclerosis progression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601150/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39601150</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324638>10.1161/CIRCRESAHA.124.324638</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601150</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Seien Ko</dc:creator>
<dc:creator>Atsushi Anzai</dc:creator>
<dc:creator>Xueyuan Liu</dc:creator>
<dc:creator>Kenichiro Kinouchi</dc:creator>
<dc:creator>Kazuhiro Yamanoi</dc:creator>
<dc:creator>Takuto Torimitsu</dc:creator>
<dc:creator>Genki Ichihara</dc:creator>
<dc:creator>Hiroki Kitakata</dc:creator>
<dc:creator>Kohsuke Shirakawa</dc:creator>
<dc:creator>Yoshinori Katsumata</dc:creator>
<dc:creator>Jin Endo</dc:creator>
<dc:creator>Kaori Hayashi</dc:creator>
<dc:creator>Masahide Yoshida</dc:creator>
<dc:creator>Katsuhiko Nishimori</dc:creator>
<dc:creator>Kenji F Tanaka</dc:creator>
<dc:creator>Tatsushi Onaka</dc:creator>
<dc:creator>Motoaki Sano</dc:creator>
<dc:creator>Masaki Ieda</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Social Bonds Retain Oxytocin-Mediated Brain-Liver Axis to Retard Atherosclerosis</dc:title>
<dc:identifier>pmid:39601150</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324638</dc:identifier>
</item>
<item>
<title>Neutrophil CRACR2A Promotes Neutrophil Recruitment in Sterile Inflammation and Ischemic Stroke</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our results demonstrate that neutrophil CRACR2A promotes neutrophil recruitment to sites of sterile inflammation, such as ischemic stroke. Blocking the STIM1-CRACR2A interaction may be a novel therapeutic strategy to mitigate inflammation and consequent tissue injury.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 27. doi: 10.1161/CIRCULATIONAHA.124.070487. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> channel regulator 2A (CRACR2A) has been linked to immunodeficiency attributable to T-cell dysfunction in humans. We discovered that neutrophil CRACR2A promotes neutrophil adhesive and migratory functions by facilitating Ca<sup>2+</sup> mobilization and β2 integrin activation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Myeloid-specific cracr2a conditional knockout mice and intravital microscopy were used to investigate the physiologic role of neutrophil cracr2a in neutrophil recruitment in vascular inflammation. Cracr2a-deficient neutrophils or dHL-60 (differentiated human neutrophil-like) cells and CRACR2A-derived peptides were used in flow cytometry, immunoprecipitation, cytosolic Ca<sup>2+</sup> mobilization, and flow chamber assays to elucidate the molecular mechanism. Four-dimensional confocal intravital microscopy of mice after focal brain ischemia and single neutrophil behavioral analysis demonstrated the pathologic role of neutrophil cracr2a in brain damage.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with wild-type control mice, cracr2a conditional knockout mice exhibited significantly reduced adhesion, crawling, and transmigration of neutrophils on ear and cremaster venules in tumor necrosis factor-α-induced sterile inflammation. Neutrophil cracr2a rapidly interacts with STIM1 (stromal interaction molecule 1) after agonist stimulation and facilitates Ca<sup>2+</sup> mobilization, increasing the ligand-binding function of β2 integrin. Our findings in cracr2a-deficient mouse neutrophils are recapitulated in dHL-60 cells, in which CRACR2A is deleted by CRISPR/Cas9. Furthermore, overexpression of CRACR2A in CRACR2A KO dHL-60 cells restores normal function. Using a series of peptides covering the coiled-coil region of CRACR2A, we identified a palmitoylated 20-mer that blocks STIM1-CRACR2A interaction. Treating neutrophils with this 20-mer inhibits Ca<sup>2+</sup> mobilization and β2 integrin activation after agonist stimulation, reducing neutrophil recruitment to an activated endothelial cell monolayer under venous shear stress and to ear venules in tumor necrosis factor-α-challenged mice. Cerebral 4-dimensional intravital microscopy of mice after focal brain ischemia revealed that neutrophil cracr2a enhances the emergence of highly migratory neutrophils by increasing the surface level of αMβ2 integrin, thereby facilitating neutrophil infiltration into brain tissue and exacerbating brain injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results demonstrate that neutrophil CRACR2A promotes neutrophil recruitment to sites of sterile inflammation, such as ischemic stroke. Blocking the STIM1-CRACR2A interaction may be a novel therapeutic strategy to mitigate inflammation and consequent tissue injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39601147</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070487>10.1161/CIRCULATIONAHA.124.070487</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601147</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jingu Lee</dc:creator>
<dc:creator>Brett Balzraine</dc:creator>
<dc:creator>Alexis Schweizer</dc:creator>
<dc:creator>Vasilisa Kuzmanova</dc:creator>
<dc:creator>Yousang Gwack</dc:creator>
<dc:creator>Babak Razani</dc:creator>
<dc:creator>Jin-Moo Lee</dc:creator>
<dc:creator>Deane F Mosher</dc:creator>
<dc:creator>Jaehyung Cho</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Neutrophil CRACR2A Promotes Neutrophil Recruitment in Sterile Inflammation and Ischemic Stroke</dc:title>
<dc:identifier>pmid:39601147</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070487</dc:identifier>
</item>
<item>
<title>Declining Trend of Sudden Cardiac Death in Younger Individuals: A 20-Year Nationwide Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601123/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SCD incidence rates in young individuals declined by 49% over the past 2 decades. The decline was paralleled by improved survival of OHCA, higher diagnostic rates of inherited cardiac diseases, and higher ICD implantation rates. However, rates of unwitnessed SCD were unchanged, which calls for new perspectives in preventive strategies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 27. doi: 10.1161/CIRCULATIONAHA.124.069431. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Declining cardiovascular mortality rates have been well-documented, yet temporal trends of sudden cardiac death (SCD) in young individuals remain unclear. We provide contemporary nationwide estimates of the temporal trends of SCD in young individuals (1-35 years of age) from 2000 through 2019 and correlate these trends to changes in out-of-hospital cardiac arrest (OHCA) patterns, rates of inherited cardiac diseases, and implantations of implantable cardioverter defibrillators (ICD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All individuals between 1 and 35 years of age living in Denmark from 2000 through 2019 were included, with annual re-evaluation of the at-risk population in regard to age. Adjudication of SCD cases relied on multiple sources, including death certificates, medical files, and autopsy reports. Information on OHCA, diagnostic rates, and ICD implantations were captured from nationwide administrative registries. Annual incidence rates of SCD were calculated, and temporal trends in SCD incidence were computed as percentage change annualized. Trends in OHCA survival and characteristics, diagnostic rates of inherited cardiac diseases, and ICD implantations were assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the 20-year study period (47.5 million person-years), 1057 SCDs were identified (median age, 29 years; 69% male). The overall incidence of SCD was 2.2 per 100 000 person-years and declined by 3.31% (95% CI, 2.42-4.20) annually, corresponding to a 49% (95% CI, 38.7-57.6) reduction during the study. Rates of witnessed SCD declined markedly (percentage change annualized -7.03% [95% CI, -8.57 to -5.48]), but we observed no changes in the rate of unwitnessed SCD (percentage change annualized -0.09% [95% CI, -1.48 to 1.31]). Therefore, the proportion of unwitnessed SCD increased by 79% (<i>P</i>&lt;0.001). Survival after OHCA in young individuals (1 to 35 years of age) increased from 3.9% to 28%, mainly because of increased bystander cardiopulmonary resuscitation and defibrillation rates. Diagnostic rates of inherited cardiac diseases increased 10-fold (incidence rate ratio, 10.4 [95% CI, 8.46-12.90]) and the ICD implantation rate increased 2-fold (incidence rate ratio, 1.97 [95% CI, 1.51-2.60]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SCD incidence rates in young individuals declined by 49% over the past 2 decades. The decline was paralleled by improved survival of OHCA, higher diagnostic rates of inherited cardiac diseases, and higher ICD implantation rates. However, rates of unwitnessed SCD were unchanged, which calls for new perspectives in preventive strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601123/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39601123</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069431>10.1161/CIRCULATIONAHA.124.069431</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601123</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Carl Johann Hansen</dc:creator>
<dc:creator>Jesper Svane</dc:creator>
<dc:creator>Peder Emil Warming</dc:creator>
<dc:creator>Thomas Hadberg Lynge</dc:creator>
<dc:creator>Rodrigue Garcia</dc:creator>
<dc:creator>Carolina Malta Hansen</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Jytte Banner</dc:creator>
<dc:creator>Bo Gregers Winkel</dc:creator>
<dc:creator>Jacob Tfelt-Hansen</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Declining Trend of Sudden Cardiac Death in Younger Individuals: A 20-Year Nationwide Study</dc:title>
<dc:identifier>pmid:39601123</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069431</dc:identifier>
</item>
<item>
<title>Mechano-dependent sorbitol accumulation supports biomolecular condensate</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39591966/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>Condensed droplets of protein regulate many cellular functions, yet the physiological conditions regulating their formation remain largely unexplored. Increasing our understanding of these mechanisms is paramount, as failure to control condensate formation and dynamics can lead to many diseases. Here, we provide evidence that matrix stiffening promotes biomolecular condensation in vivo. We demonstrate that the extracellular matrix links mechanical cues with the control of glucose metabolism to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 16:S0092-8674(24)01271-6. doi: 10.1016/j.cell.2024.10.048. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Condensed droplets of protein regulate many cellular functions, yet the physiological conditions regulating their formation remain largely unexplored. Increasing our understanding of these mechanisms is paramount, as failure to control condensate formation and dynamics can lead to many diseases. Here, we provide evidence that matrix stiffening promotes biomolecular condensation in vivo. We demonstrate that the extracellular matrix links mechanical cues with the control of glucose metabolism to sorbitol. In turn, sorbitol acts as a natural crowding agent to promote biomolecular condensation. Using in silico simulations and in vitro assays, we establish that variations in the physiological range of sorbitol concentrations, but not glucose concentrations, are sufficient to regulate biomolecular condensates. Accordingly, pharmacological and genetic manipulation of intracellular sorbitol concentration modulates biomolecular condensates in breast cancer-a mechano-dependent disease. We propose that sorbitol is a mechanosensitive metabolite enabling protein condensation to control mechano-regulated cellular functions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39591966/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39591966</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.048>10.1016/j.cell.2024.10.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39591966</guid>
<pubDate>Tue, 26 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Stephanie Torrino</dc:creator>
<dc:creator>William M Oldham</dc:creator>
<dc:creator>Andrés R Tejedor</dc:creator>
<dc:creator>Ignacio S Burgos</dc:creator>
<dc:creator>Lara Nasr</dc:creator>
<dc:creator>Nesrine Rachedi</dc:creator>
<dc:creator>Kéren Fraissard</dc:creator>
<dc:creator>Caroline Chauvet</dc:creator>
<dc:creator>Chaima Sbai</dc:creator>
<dc:creator>Brendan P O'Hara</dc:creator>
<dc:creator>Sophie Abélanet</dc:creator>
<dc:creator>Frederic Brau</dc:creator>
<dc:creator>Cyril Favard</dc:creator>
<dc:creator>Stephan Clavel</dc:creator>
<dc:creator>Rosana Collepardo-Guevara</dc:creator>
<dc:creator>Jorge R Espinosa</dc:creator>
<dc:creator>Issam Ben-Sahra</dc:creator>
<dc:creator>Thomas Bertero</dc:creator>
<dc:date>2024-11-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mechano-dependent sorbitol accumulation supports biomolecular condensate</dc:title>
<dc:identifier>pmid:39591966</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.048</dc:identifier>
</item>
<item>
<title>ACSL4 and polyunsaturated lipids support metastatic extravasation and colonization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39591965/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>Metastatic dissemination to distant organs demands that cancer cells possess high morphological and metabolic adaptability. However, contributions of the cellular lipidome to metastasis remain elusive. Here, we uncover a correlation between metastasis potential and ferroptosis susceptibility in multiple cancers. Metastases-derived cancer cells exhibited higher ferroptosis sensitivity and polyunsaturated fatty acyl (PUFA)-lipid contents than primary-tumor-derived cells from ovarian cancer...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 19:S0092-8674(24)01270-4. doi: 10.1016/j.cell.2024.10.047. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Metastatic dissemination to distant organs demands that cancer cells possess high morphological and metabolic adaptability. However, contributions of the cellular lipidome to metastasis remain elusive. Here, we uncover a correlation between metastasis potential and ferroptosis susceptibility in multiple cancers. Metastases-derived cancer cells exhibited higher ferroptosis sensitivity and polyunsaturated fatty acyl (PUFA)-lipid contents than primary-tumor-derived cells from ovarian cancer patients. Metabolism-focused CRISPR screens in a mouse model for ovarian cancer distant metastasis established via two rounds of in vivo selection revealed the PUFA-lipid biosynthesis enzyme acyl-coenzyme A (CoA) synthetase long-chain family member 4 (ACSL4) as a pro-hematogenous metastasis factor. ACSL4 promotes metastatic extravasation by enhancing membrane fluidity and cellular invasiveness. While promoting metastasis, the high PUFA-lipid state creates dependencies on abhydrolase-domain-containing 6, acylglycerol lipase (ABHD6), enoyl-CoA delta isomerase 1 (ECI1), and enoyl-CoA hydratase 1 (ECH1)-rate-limiting enzymes preparing unsaturated fatty acids (UFAs) for β-oxidation. ACSL4/ECH1 co-inhibition achieved potent suppression of metastasis. Our work establishes the dual functions of PUFA-lipids in tumor progression and metastasis that may be exploitable for therapeutic development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39591965/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39591965</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.047>10.1016/j.cell.2024.10.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39591965</guid>
<pubDate>Tue, 26 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yuqi Wang</dc:creator>
<dc:creator>Mangze Hu</dc:creator>
<dc:creator>Jian Cao</dc:creator>
<dc:creator>Fengxiang Wang</dc:creator>
<dc:creator>Jingrong Regina Han</dc:creator>
<dc:creator>Tianshu William Wu</dc:creator>
<dc:creator>Luxiao Li</dc:creator>
<dc:creator>Jinshi Yu</dc:creator>
<dc:creator>Yujing Fan</dc:creator>
<dc:creator>Guanglei Xie</dc:creator>
<dc:creator>Heyuan Lian</dc:creator>
<dc:creator>Yueying Cao</dc:creator>
<dc:creator>Nathchar Naowarojna</dc:creator>
<dc:creator>Xi Wang</dc:creator>
<dc:creator>Yilong Zou</dc:creator>
<dc:date>2024-11-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>ACSL4 and polyunsaturated lipids support metastatic extravasation and colonization</dc:title>
<dc:identifier>pmid:39591965</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.047</dc:identifier>
</item>
<item>
<title>Accelerated atrial pacing reduces left-heart filling pressure: a combined clinical-computational study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39589540/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Accelerated pacing acutely reduces left-heart filling pressure in patients undergoing AF catheter ablation and computer simulations with HFpEF features, suggesting it as a potential therapeutic strategy to alleviate congestion symptoms. Virtual HFpEF patient cohorts hypothesize that AV sequential pacing may further optimize this therapy's beneficial effects.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 26:ehae718. doi: 10.1093/eurheartj/ehae718. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Accelerated atrial pacing offers potential benefits for patients with heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF), compared with standard lower-rate pacing. The study investigates the relationship between atrial pacing rate and left-heart filling pressure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Seventy-five consecutive patients undergoing catheter ablation for AF underwent assessment of mean left atrial pressure (mLAP) and atrioventricular (AV) conduction delay (PR interval) in sinus rhythm and accelerated atrial pacing with 10 bpm increments up to Wenckebach block. Computer simulations (CircAdapt) of a virtual HFpEF cohort complemented clinical observations and hypothesized the modulating effects of AV coupling and atrial (dys)function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the study cohort, 49(65%) patients had a high HFpEF likelihood (H2FPEF ≥ 5.0), and 28(37%) an elevated mLAP ≥ 15 mmHg at sinus rhythm. Optimal pacing rates of 100 [70-110]bpm (median [IQR]) significantly reduced mLAP from 12.8 [10.0-17.4]mmHg in sinus rhythm (55 [52-61]bpm) to 10.4 [7.8-14.8]mmHg (P &lt; .001). Conversely, higher pacing rates (130 [110-140]bpm) significantly increased mLAP to 14.7 [11.0-17.8]mmHg (P &lt; .05). PR interval and, hence, AV conduction delay prolonged incrementally with increasing pacing rates. Simulations corroborated these clinical findings, showing mLAP reduction at a moderately increased pacing rate and a subsequent increase at higher rates. Moreover, simulations suggested that mLAP reduction is optimized when AV conduction delay shortens with increasing rate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Accelerated pacing acutely reduces left-heart filling pressure in patients undergoing AF catheter ablation and computer simulations with HFpEF features, suggesting it as a potential therapeutic strategy to alleviate congestion symptoms. Virtual HFpEF patient cohorts hypothesize that AV sequential pacing may further optimize this therapy's beneficial effects.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39589540/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39589540</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae718>10.1093/eurheartj/ehae718</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39589540</guid>
<pubDate>Tue, 26 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Tim van Loon</dc:creator>
<dc:creator>Jesse Rijks</dc:creator>
<dc:creator>Johan van Koll</dc:creator>
<dc:creator>Joey Wolffs</dc:creator>
<dc:creator>Richard Cornelussen</dc:creator>
<dc:creator>Nick van Osta</dc:creator>
<dc:creator>Justin Luermans</dc:creator>
<dc:creator>Frits Prinzen</dc:creator>
<dc:creator>Dominik Linz</dc:creator>
<dc:creator>Vanessa van Empel</dc:creator>
<dc:creator>Tammo Delhaas</dc:creator>
<dc:creator>Kevin Vernooy</dc:creator>
<dc:creator>Joost Lumens</dc:creator>
<dc:date>2024-11-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Accelerated atrial pacing reduces left-heart filling pressure: a combined clinical-computational study</dc:title>
<dc:identifier>pmid:39589540</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae718</dc:identifier>
</item>
<item>
<title>Accelerated pacing as a treatment for heart failure with preserved ejection fraction and atrial fibrillation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39589479/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 26:ehae766. doi: 10.1093/eurheartj/ehae766. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39589479/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39589479</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae766>10.1093/eurheartj/ehae766</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39589479</guid>
<pubDate>Tue, 26 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Markus Meyer</dc:creator>
<dc:date>2024-11-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Accelerated pacing as a treatment for heart failure with preserved ejection fraction and atrial fibrillation?</dc:title>
<dc:identifier>pmid:39589479</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae766</dc:identifier>
</item>
<item>
<title>Extracellular Role for the Intracellular Cell Death Mediator RIPK3 in Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585932/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 26;150(22):1812-1814. doi: 10.1161/CIRCULATIONAHA.124.072172. Epub 2024 Nov 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585932/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39585932</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11594480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">PMC11594480</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072172>10.1161/CIRCULATIONAHA.124.072172</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585932</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Dongze Qin</dc:creator>
<dc:creator>Radheshyam Modanwal</dc:creator>
<dc:creator>Richard N Kitsis</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Extracellular Role for the Intracellular Cell Death Mediator RIPK3 in Myocardial Infarction</dc:title>
<dc:identifier>pmid:39585932</dc:identifier>
<dc:identifier>pmc:PMC11594480</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072172</dc:identifier>
</item>
<item>
<title>Letter by Zhang et al Regarding Article, "Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 26;150(22):e467. doi: 10.1161/CIRCULATIONAHA.124.070129. Epub 2024 Nov 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39585931</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070129>10.1161/CIRCULATIONAHA.124.070129</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585931</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Meng Zhang</dc:creator>
<dc:creator>Xudong Pan</dc:creator>
<dc:creator>Xiaoyan Zhu</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhang et al Regarding Article, "Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era"</dc:title>
<dc:identifier>pmid:39585931</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070129</dc:identifier>
</item>
<item>
<title>Technologic Advances in Cardiac Electrophysiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585930/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 26;150(22):1745-1746. doi: 10.1161/CIRCULATIONAHA.124.071542. Epub 2024 Nov 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585930/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39585930</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071542>10.1161/CIRCULATIONAHA.124.071542</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585930</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:creator>Augustus Grant</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Technologic Advances in Cardiac Electrophysiology</dc:title>
<dc:identifier>pmid:39585930</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071542</dc:identifier>
</item>
<item>
<title>Cardiovascular Complications and Their Association With Short- and Long-Term Outcomes in Patients With Multiple Myeloma and Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585929/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 26;150(22):1815-1817. doi: 10.1161/CIRCULATIONAHA.124.070432. Epub 2024 Nov 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585929/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39585929</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070432>10.1161/CIRCULATIONAHA.124.070432</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585929</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Osnat Itzhaki Ben Zadok</dc:creator>
<dc:creator>Panagiotis Simitsis</dc:creator>
<dc:creator>Caron Jacobson</dc:creator>
<dc:creator>Omar Nadeem</dc:creator>
<dc:creator>Matthew J Frigault</dc:creator>
<dc:creator>Noopur Raje</dc:creator>
<dc:creator>Caitlyn Duffy</dc:creator>
<dc:creator>Patrick Costello</dc:creator>
<dc:creator>Jamie Dela Cruz</dc:creator>
<dc:creator>Andrew Looka</dc:creator>
<dc:creator>Anju Nohria</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Complications and Their Association With Short- and Long-Term Outcomes in Patients With Multiple Myeloma and Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Therapy</dc:title>
<dc:identifier>pmid:39585929</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070432</dc:identifier>
</item>
<item>
<title>PIEZO1 attenuates Marfan syndrome aneurysm development through TGF-β signaling pathway inhibition via TGFBR2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Piezo1 deficiency aggravates MFS aneurysms by promoting TGF-β signalling pathway activation via TGF-β receptor 2 endocytosis and a decrease in autophagy. These data suggest that PIEZO1 may be a potential therapeutic target for MFS treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 25:ehae786. doi: 10.1093/eurheartj/ehae786. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Marfan syndrome (MFS) is a hereditary disorder primarily caused by mutations in the FBN1 gene. Its critical cardiovascular manifestation is thoracic aortic aneurysm (TAA), which poses life-threatening risks. Owing to the lack of effective pharmacological therapies, surgical intervention continues to be the current definitive treatment. In this study, the role of Piezo-type mechanosensitive ion channel component 1 (Piezo1) in MFS was investigated and the activation of PIEZO1 was identified as a potential treatment for MFS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PIEZO1 expression was detected in MFS mice (Fbn1C1041G/+) and patients. Piezo1 conditional knockout mice in vascular smooth muscle cells of MFS mice (MFS × CKO) was generated, and bioinformatics analysis and experiments in vitro and in vivo were performed to investigate the role of Piezo1 in MFS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: PIEZO1 expression decreased in the aortas of MFS mice; MFS × CKO mice showed aggravated TAA, inflammation, extracellular matrix remodelling, and TGF-β pathway activation compared to MFS mice. Mechanistically, PIEZO1 knockout exacerbated the activation of the TGF-β signalling pathway by inhibiting the endocytosis and autophagy of TGF-β receptor 2 mediated by Rab GTPase 3C. Additionally, the pharmacological activation PIEZO1 through Yoda1 prevented TGF-β signalling pathway activation and reversed TAA in MFS mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Piezo1 deficiency aggravates MFS aneurysms by promoting TGF-β signalling pathway activation via TGF-β receptor 2 endocytosis and a decrease in autophagy. These data suggest that PIEZO1 may be a potential therapeutic target for MFS treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39585648</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae786>10.1093/eurheartj/ehae786</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585648</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Peiwen Yang</dc:creator>
<dc:creator>Hao Liu</dc:creator>
<dc:creator>Shilin Wang</dc:creator>
<dc:creator>Xiaoyue Xiao</dc:creator>
<dc:creator>Lang Jiang</dc:creator>
<dc:creator>Sheng Le</dc:creator>
<dc:creator>Shanshan Chen</dc:creator>
<dc:creator>Ping Ye</dc:creator>
<dc:creator>Jiahong Xia</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>PIEZO1 attenuates Marfan syndrome aneurysm development through TGF-β signaling pathway inhibition via TGFBR2</dc:title>
<dc:identifier>pmid:39585648</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae786</dc:identifier>
</item>
<item>
<title>Loss of the Endothelial Glycocalyx Component EMCN Leads to Glomerular Impairment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39584795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: Our study demonstrates a critical role of the endothelial marker EMCN in supporting normal glomerular filtration barrier structure and function by maintaining glomerular endothelial tight junction and homeostasis and podocyte function through endothelial-podocyte crosstalk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Nov 25. doi: 10.1161/CIRCRESAHA.124.325218. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: EMCN (endomucin), an endothelial-specific glycocalyx component, was found to be highly expressed by the endothelium of the renal glomerulus. We reported an anti-inflammatory role of EMCN and its involvement in the regulation of VEGF (vascular endothelial growth factor) activity through modulating VEGFR2 (VEGF receptor 2) endocytosis. The goal of this study is to investigate the phenotypic and functional effects of EMCN deficiency using the first global EMCN knockout mouse model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Global EMCN knockout mice were generated by crossing EMCN-floxed mice with ROSA26-Cre mice. Flow cytometry was used to analyze infiltrating myeloid cells in the kidneys. The ultrastructure of the glomerular filtration barrier was examined by transmission electron microscopy, whereas urinary albumin, creatinine, and total protein levels were analyzed from freshly collected urine samples. Expression and localization of EMCN, EGFP, CD45, CD31, CD34, podocin, and albumin were examined by immunohistochemistry. Mice were weighed regularly, and their systemic blood pressure was measured using a noninvasive tail-cuff system. Glomerular endothelial cells and podocytes were isolated by fluorescence-activated cell sorting for RNA sequencing. Transcriptional profiles were analyzed to identify differentially expressed genes in both endothelium and podocytes, followed by gene ontology analysis. Protein levels of EMCN, albumin, and podocin were quantified by Western blot.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The EMCN<sup>-/-</sup> mice exhibited increased infiltration of CD45<sup>+</sup> cells, with an increased proportion of Ly6G<sup>high</sup>Ly6C<sup>high</sup> myeloid cells and higher VCAM-1 (vascular cell adhesion molecule 1) expression. EMCN<sup>-/-</sup> mice displayed albuminuria with increased albumin in the Bowman's space compared with the EMCN<sup>+/+</sup> littermates. Glomeruli in EMCN<sup>-/-</sup> mice revealed fused and effaced podocyte foot processes and disorganized endothelial fenestrations. We found no significant difference in blood pressure between EMCN knockout mice and their wild-type littermates. RNA sequencing of glomerular endothelial cells revealed downregulation of cell-cell adhesion and MAPK (mitogen-activated protein kinase)/ERK (extracellular signal-regulated kinase) pathways, along with glycocalyx and extracellular matrix remodeling. In podocytes, we observed reduced VEGF signaling and alterations in cytoskeletal organization. Notably, there was a significant decrease in both mRNA and protein levels of podocin, a key component of the slit diaphragm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Our study demonstrates a critical role of the endothelial marker EMCN in supporting normal glomerular filtration barrier structure and function by maintaining glomerular endothelial tight junction and homeostasis and podocyte function through endothelial-podocyte crosstalk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39584795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39584795</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325218>10.1161/CIRCRESAHA.124.325218</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39584795</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Zhengping Hu</dc:creator>
<dc:creator>Issahy Cano</dc:creator>
<dc:creator>Fengyang Lei</dc:creator>
<dc:creator>Jie Liu</dc:creator>
<dc:creator>Ramon Bossardi Ramos</dc:creator>
<dc:creator>Harper Gordon</dc:creator>
<dc:creator>Eleftherios I Paschalis</dc:creator>
<dc:creator>Magali Saint-Geniez</dc:creator>
<dc:creator>Yin Shan Eric Ng</dc:creator>
<dc:creator>Patricia A D'Amore</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Loss of the Endothelial Glycocalyx Component EMCN Leads to Glomerular Impairment</dc:title>
<dc:identifier>pmid:39584795</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325218</dc:identifier>
</item>
<item>
<title>Targeting fibroblast phenotype switching in cardiac remodelling as a promising antifibrotic strategy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39582108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>Myocardial fibrosis, a common feature of heart disease, remains an unsolved clinical challenge. Fibrosis resolution requires activation of cardiac fibroblasts exhibiting context-dependent beneficial and detrimental dichotomy. Here, we explored the hypothesis of fibroblast reversible transition between quiescence and activated myofibroblastic states as a manifestation of cell phenotypic switching in myocardial remodelling. In support, gene regulatory networks executing conversion of cardiac...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 25:ehae722. doi: 10.1093/eurheartj/ehae722. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Myocardial fibrosis, a common feature of heart disease, remains an unsolved clinical challenge. Fibrosis resolution requires activation of cardiac fibroblasts exhibiting context-dependent beneficial and detrimental dichotomy. Here, we explored the hypothesis of fibroblast reversible transition between quiescence and activated myofibroblastic states as a manifestation of cell phenotypic switching in myocardial remodelling. In support, gene regulatory networks executing conversion of cardiac fibroblasts to myofibroblasts and vice versa in fibrosis resolution are reconstructed using TRANSPATH database. In a scenario of fibroblast activation triggered by transforming growth factor β, a cardinal mediator of tissue fibrosis, signalling cascades governing entry into or exit from specific fibroblast statures in cardiac fibrotic remodelling were dissected. It is suggested that fibroblast phenotypic switching constitutes the central gait toward guiding cell state-gating strategies to counteract adverse cardiac fibrosis, a devastating disorder with no approved therapeutic option.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39582108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39582108</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae722>10.1093/eurheartj/ehae722</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39582108</guid>
<pubDate>Sun, 24 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Alexander Kel</dc:creator>
<dc:creator>Thomas Thum</dc:creator>
<dc:creator>Oksana Kunduzova</dc:creator>
<dc:date>2024-11-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Targeting fibroblast phenotype switching in cardiac remodelling as a promising antifibrotic strategy</dc:title>
<dc:identifier>pmid:39582108</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae722</dc:identifier>
</item>
<item>
<title>A Contemporary Picture of Coagulase-Negative Staphylococcal Endocarditis: A Nationwide GAMES Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39580721/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CoNSIE was a relatively common (18.4%) and life-threatening entity with particularities by species yet generally high rates of surgery and mortality, although its prognosis improved over time.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 25:S0735-1097(24)08573-5. doi: 10.1016/j.jacc.2024.09.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Coagulase-negative staphylococci (CoNS) are an increasingly common cause of infective endocarditis (IE) and lack recent data from large studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: Our aim was to describe the epidemiology, clinical characteristics, and outcomes of staphylococcal IE in a contemporary nationwide cohort study, while comparing coagulase-negative staphylococcal IE (CoNSIE) to IE from Staphylococcus aureus (SAIE), and among IE caused by Staphylococcus epidermidis (SE), S. lugdunensis (SL), and other CoNS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We completed a post hoc analysis of a prospectively collected cohort of 4,567 consecutive definitive IE episodes from 44 Spanish centers between 2008 and 2022 (GAMES ["Grupos de Apoyo al Manejo de la Endocarditis Infecciosa en España"] cohort). A total of 842 cases of CoNSIE were compared with 1,109 cases of SAIE. Additionally, 647 episodes caused by SE were compared with 54 caused by SL and 109 caused by 9 other known CoNS species. Multivariate analyses were performed to investigate prognostic factors for in-hospital and 1-year mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Staphylococci accounted for 1,951 (42.7%) episodes of IE. The predominant CoNS etiology was SE (76.8%), followed by SL (6.4%), S. capitis (3.5%), S. haemolyticus (3.2%), S. hominis (3.2%), S. warneri (1.5%), and 5 other species. CoNSIE showed a distinct clinical profile from SAIE (older age, higher rates of prior heart disease, aortic and prosthetic valve involvement, nosocomial acquisition, methicillin resistance, intracardiac complications, and cardiac surgery), while in-hospital mortality was higher in SAIE (32.8% vs 37.1%; P = 0.049), with no significant differences in 1-year mortality. S. lugdunensis displayed a shorter course of infection and higher rates of leaflet perforation/rupture than S. epidermidis and other CoNS, but cardiac surgery rates (60.4% vs 61.1% vs 56.0%; P = 0.850), as well as in-hospital (33.1% vs 37.0% vs 27.5%; P = 0.540) and 1-year mortality rates were high and similar in all groups. Septic shock, heart failure, and cardiac surgery (protective) were consistently identified as independent prognostic factors, whereas none of the staphylococcal species were independently associated with mortality. Last, each 5-year study period was independently associated with a reduction in staphylococcal in-hospital and 1-year mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CoNSIE was a relatively common (18.4%) and life-threatening entity with particularities by species yet generally high rates of surgery and mortality, although its prognosis improved over time.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39580721/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39580721</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.027>10.1016/j.jacc.2024.09.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39580721</guid>
<pubDate>Sun, 24 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Clara Palom-Grau</dc:creator>
<dc:creator>Guillermo Cuervo</dc:creator>
<dc:creator>Patricia Muñoz</dc:creator>
<dc:creator>Mercedes Marín Arriaza</dc:creator>
<dc:creator>Manuel Martínez-Sellés</dc:creator>
<dc:creator>Víctor González-Ramallo</dc:creator>
<dc:creator>Arístides de Alarcón</dc:creator>
<dc:creator>Manuel Poyato-Borrego</dc:creator>
<dc:creator>Raquel Rodríguez-García</dc:creator>
<dc:creator>M Ángeles Rodríguez-Esteban</dc:creator>
<dc:creator>M Carmen Fariñas</dc:creator>
<dc:creator>Claudia González-Rico</dc:creator>
<dc:creator>Miguel Ángel Goenaga</dc:creator>
<dc:creator>Guillermo Ojeda-Burgos</dc:creator>
<dc:creator>Ane Josune Goikoetxea-Agirre</dc:creator>
<dc:creator>Jorge Calderón-Parra</dc:creator>
<dc:creator>Juan Carlos López-Azor</dc:creator>
<dc:creator>Elisa García-Vázquez</dc:creator>
<dc:creator>Belén Loeches</dc:creator>
<dc:creator>Eduard Quintana</dc:creator>
<dc:creator>Cristina García de la Mària</dc:creator>
<dc:creator>Jaume Llopis</dc:creator>
<dc:creator>José M Miró</dc:creator>
<dc:creator>GAMES Investigators</dc:creator>
<dc:date>2024-11-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Contemporary Picture of Coagulase-Negative Staphylococcal Endocarditis: A Nationwide GAMES Cohort Study</dc:title>
<dc:identifier>pmid:39580721</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.027</dc:identifier>
</item>
<item>
<title>CoN(S) Nuevas Perspectivas: Insights Into Coagulase-Negative Staphylococcal Infective Endocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39580720/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241127231422&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 19:S0735-1097(24)10421-4. doi: 10.1016/j.jacc.2024.10.110. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39580720/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241127231422&v=2.18.0.post9+e462414">39580720</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.110>10.1016/j.jacc.2024.10.110</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39580720</guid>
<pubDate>Sun, 24 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Supavit Chesdachai</dc:creator>
<dc:creator>Daniel C DeSimone</dc:creator>
<dc:creator>Larry M Baddour</dc:creator>
<dc:date>2024-11-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>CoN(S) Nuevas Perspectivas: Insights Into Coagulase-Negative Staphylococcal Infective Endocarditis</dc:title>
<dc:identifier>pmid:39580720</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.110</dc:identifier>
</item>





























</channel>
</rss>